Imugene Share Price and Company Fundamentals
Last traded: Today at 5:10 AM
Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study. The company also develops CF33 oncolytic virotherapy; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic gastric cancer; HERIZON, which is in Phase 1b/2 study for HER-Vaxx and chemotherapy; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and NeoPOLEM in phase 2 study for MSI-high colorectal cancer. Imugene Limited is headquartered in Sydney, Australia.
Key Metrics
PE ratio
-
PB ratio
1.29
Dividend yield
-
Beta
2.59
Market cap
$86.06M
Enterprise value
$68.05M
Company profile
| Industry / Sector | Biotechnology / Healthcare |
|---|---|
| Website | https://www.imugene.com |
| Mailing address | 4-6 Bligh Street Suite 12.01, Level 12 Sydney NSW 2000 Australia |
| Phone / Fax | 61 2 9423 0881 / 61 2 9423 0881 |
Dividends
More: Imugene Dividend history, yield and payout ratio
Dividend yield
-
Dividend amount
$-
Payout ratio
0.00%
5Y Avg. yield
-%
Imugene paid $- dividend and the ex-dividend date was -.The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.IMU dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
Company Executives
As of Feb 2026, following are the company executives and directors listed on Imugene.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD | Executive Chairman | 69 | |
| Ms. Leslie Chong | CEO, MD & Executive Director | ||
| Mr. Darren Michael Keamy B.Com., CPA | CFO & Company Secretary | 52 | |
| Dr. John Byon M.D., Ph.D. | Chief Medical Officer | ||
| Ms. Ursula McCurry | Chief Clinical Operations Officer |
Profitability and management effectiveness
Profit margin
0.00%
Operating margin
-644.78%
Return on assets
-37.27%
Return on equity
-84.54%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Imugene is 86.06M and its enterprise value is 68.05M. The enterprise value to revenue ratio of IMU is 15.48. The enterprise value to EBITDA ratio of IMU is -1.01.
The IMU's stocks Beta value is 2.59 making it 159% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Imugene (IMU)
Imugene (ASX:IMU) Frequently Asked Questions
1. What is Imugene's Stock Symbol?
Imugene trades on ASX under the ticker symbol "IMU".
2. What is Imugene's stock price today?
One share of IMU stock can currently be purchased for approximately $0.265.
3. How can I contact Imugene?
Imugene's mailing address is 4-6 Bligh Street Suite 12.01, Level 12 Sydney NSW 2000 Australia. The company can be reached via phone at 61 2 9423 0881.
4. What is Imugene's official website?
The official website of Imugene is https://www.imugene.com.